Page 167 - Neuropsychiatric.indd

30. Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Development of
a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm. 2017;39(2):424-

32.
31. Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-wide QT
alert system identifies patients with a high risk of mortality. Mayo Clin Proc. 2013;88(4):315-
25.

32. Tisdale risk score for QT prolongation. [accessed 29 November 2020]. Available from:
https://www.mdcalc.com/tisdale-risk-score-qt-prolongation
33. Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT

prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452-8.
34. Lexi-drugs online. Lexicomp, Inc.; 2021 [accessed 20 February 2021]. Available from:
http://online.lexi.com. Subscription required to view.
35. Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades
de pointes. Br J Clin Pharmacol. 2016;81(3):420-7.

36. Arce JS, Rubén Romero, Paula Solorzano. A case of prolonged QT Interval and torsades de
pointes due to ciprofloxacin. Rev Esp Cardiol. 2010;63(1):111-25.
37. Ayad RF, Assar MD, Simpson L, Garner JB, Schussler JM. Causes and management of drug-

induced long QT syndrome. Proc (Bayl Univ Med Cent). 2010;23(3):250–5.
38. Donthi N, Chandrabhatla T, Genovese L, deFilippi C. Fast and furious: flecainide toxicity
presenting as monomorphic ventricular tachycardia. BMJ Case Rep 2020;13:e236932.
39. Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS

Guideline for the management of adult patients with supraventricular tachycardia:
executive summary: A report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
Circulation. 2016;133(14):e471-505.

40. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al. 2019 ESC
Guidelines for the management of patients with supraventricular tachycardia The Task
Force for the management of patients with supraventricular tachycardia of the European
Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720.

41. Tisdale JE. Chapter 26 Supraventricular arrhythmia. In: Tisdale JE et al., eds. Drug-Induced
Diseases: Prevention, Detection, and Management. 3rd ed. United States: American Society
of Health-System Pharmacists, Inc., 2018.
42. Kaakeh Y, Overholser BR, Lopshire JC, Tisdale JE. Drug-induced atrial fibrillation. Drugs.

2012;72(12):1617-30.
43. Tamargo J, Caballero R, Delpon E. Drug-induced atrial fibrillation. Expert Opin Drug Saf
2012;11(4):615-34.

146
146